BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 236 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.21 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10 | -73.0% | 2 | -71.4% | 0.00% | – |
| Q2 2023 | $37 | +164.3% | 7 | -12.5% | 0.00% | – |
| Q1 2023 | $14 | -77.4% | 8 | -27.3% | 0.00% | – |
| Q4 2022 | $62 | -99.7% | 11 | -57.7% | 0.00% | -100.0% |
| Q3 2022 | $21,000 | +16.7% | 26 | +18.2% | 0.00% | 0.0% |
| Q2 2022 | $18,000 | -35.7% | 22 | -31.2% | 0.00% | 0.0% |
| Q1 2022 | $28,000 | +16.7% | 32 | +14.3% | 0.00% | 0.0% |
| Q4 2021 | $24,000 | +71.4% | 28 | +1300.0% | 0.00% | -85.7% |
| Q3 2021 | $14,000 | -12.5% | 2 | 0.0% | 0.01% | +16.7% |
| Q2 2021 | $16,000 | -70.9% | 2 | -60.0% | 0.01% | +500.0% |
| Q1 2021 | $55,000 | – | 5 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
| Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
| Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
| Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
| AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
| TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
| Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
| DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
| Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |